CoreMedic

CoreMedic GmbH is a cardiology company established in 2012 as a spin-off from the Heart Center of the University of Bern, Switzerland. With locations in Radolfzell and Tuebingen, Germany, and Biel, Switzerland, the company specializes in developing minimally invasive medical devices and therapies for heart valve diseases, particularly mitral valve regurgitation (MR). The flagship product, the ChordArt™ mitral valve repair system, utilizes transcatheter technology for minimally invasive repair of the mitral valve at the beating heart. This system offers a catheter-based procedure that replaces damaged mitral valve chords, providing a less traumatic alternative to traditional open-heart surgery. CoreMedic's approach aims to reduce patient trauma, shorten recovery time, and expand treatment options for patients who cannot undergo conventional surgery. The team at CoreMedic includes professionals with expertise in medical applications, management, research and development, regulatory affairs, and quality assurance. The company is EN ISO 13485:2016 certified, demonstrating its commitment to quality in medical device manufacturing. CoreMedic is supported by private and institutional investors and has formed a strategic partnership with InnoRa GmbH to enhance clinical trials and further develop the ChordArt system.

• Employees 13
• Founded 2012